DW 1350

Drug Profile

DW 1350

Alternative Names: DW-1350

Latest Information Update: 12 Dec 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong Wha Pharmaceutical
  • Developer Actavis Inc; Dong Wha Pharmaceutical
  • Class Benzamidines; Osteoporosis therapies; Small molecules; Thiazoles
  • Mechanism of Action Bone resorption factor inhibitors; Leukotriene B4 receptor antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble
  • 01 Apr 2008 DW 1350 licensed to Teijin Pharna in Japan for the treatment of any indications, including Osteroporosis
  • 01 Apr 2008 Preclinical trials in Osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top